Schroder Investment Management Group Sells 13,477 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Schroder Investment Management Group lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 81,524 shares of the biopharmaceutical company's stock after selling 13,477 shares during the quarter. Schroder Investment Management Group owned approximately 0.07% of Regeneron Pharmaceuticals worth $58,072,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Intact Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $356,000. Principal Financial Group Inc. grew its holdings in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the period. Fagan Associates Inc. increased its position in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after buying an additional 3,832 shares during the last quarter. Golden State Equity Partners raised its stake in shares of Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after buying an additional 1,272 shares during the period. Finally, ABC Arbitrage SA purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $1,510,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Trading Up 1.4 %

REGN stock traded up $8.60 during trading on Wednesday, hitting $625.60. 899,886 shares of the company traded hands, compared to its average volume of 679,610. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 1 year low of $603.47 and a 1 year high of $1,211.20. The company has a 50-day moving average of $680.43 and a 200-day moving average of $786.93. The firm has a market capitalization of $68.39 billion, a PE ratio of 16.34, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the firm posted $11.86 earnings per share. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.56%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on REGN. Robert W. Baird lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research report on Monday. Finally, TD Cowen reduced their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.